SYFOVRE Drug Patent Profile

When do Syfovre patents expire, and when can generic versions of Syfovre launch?

Syfovre is a drug marketed by Apellis Pharms and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and one patent family members in thirty countries.

The generic ingredient in SYFOVRE is pegcetacoplan. One supplier is listed for this compound. Additional details are available on the pegcetacoplan profile page.

DrugPatentWatch^® Generic Entry Outlook for Syfovre

Syfovre was eligible for patent challenges on May 14, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 15, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SYFOVRE

International Patents:	201
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	4
Drug Prices:	Drug price information for SYFOVRE
What excipients (inactive ingredients) are in SYFOVRE?	SYFOVRE excipients list
DailyMed Link:	SYFOVRE at DailyMed

See drug prices for SYFOVRE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYFOVRE

Constraining patent/regulatory exclusivity:

10,035,822

NDA:

217171

Dosage:

SOLUTION;INTRAVITREAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SYFOVRE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Apellis Pharmaceuticals, Inc.	PHASE3
AbbVie	PHASE1
Hoffmann-La Roche	PHASE1

See all SYFOVRE clinical trials

Pharmacology for SYFOVRE

Drug Class	Complement Inhibitor
Mechanism of Action	Complement Inhibitors

US Patents and Regulatory Information for SYFOVRE

SYFOVRE is protected by sixteen US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,035,822.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes	12,528,836
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes	9,169,307			Y

EU/EMA Drug Approvals for SYFOVRE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Swedish Orphan Biovitrum AB (publ)	Aspaveli	pegcetacoplan	EMEA/H/C/005553Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.	Authorised	no	no	yes	2021-12-13

International Patents for SYFOVRE

When does loss-of-exclusivity occur for SYFOVRE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYFOVRE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	7093871
World Intellectual Property Organization (WIPO)	2007062249
Japan	2016505527

Supplementary Protection Certificates for SYFOVRE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3660033	CA 2022 00023	Denmark		PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214
3660033	795	Finland
3660033	C202230025	Spain		PRODUCT NAME: PEGCETACOPLAN; NATIONAL AUTHORISATION NUMBER: EU/1/21/1595; DATE OF AUTHORISATION: 20211213; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1595; DATE OF FIRST AUTHORISATION IN EEA: 20211213

Market Dynamics and Financial Trajectory for SYFOVRE

Last updated: January 17, 2026

Summary

SYFOVRE (provided under the official name of the drug, pegcetacoplan), developed by Apellis Pharmaceuticals, is an FDA-approved complement inhibitor indicated for geographic atrophy (GA), a late-stage manifestation of age-related macular degeneration (AMD). Since its approval in July 2023, SYFOVRE’s market growth prospects, competitive positioning, and financial sustainability hinge on several key factors including unmet medical needs, safety profile, pricing, reimbursement policies, competitive landscape, and regulatory environment.

This report evaluates the current market dynamics, project sales revenue trajectories through 2030, and analyzes the key drivers influencing SYFOVRE's commercial success.

---

What is SYFOVRE and How Does It Fit in the Ophthalmology Market?

Aspect	Details
Generic Name	Pegcetacoplan
Therapeutic Class	Complement pathway inhibitor; anti-complement C3 agent
Indication	Geographic atrophy secondary to age-related macular degeneration
Approval Date	July 2023 (FDA)
Administration	Intravitreal injection (monthly or bi-monthly)
Development Partner	Apellis Pharmaceuticals

Market Need:
GA affects approximately 5 million people globally, with prevalence expected to rise with aging populations. Currently, no approved therapies effectively slow or reverse GA progression, representing a significant unmet medical need.

---

Current Market Dynamics

Market Size and Growth Drivers

Parameter	Figures & Projections
Global AMD Population	~196 million in 2020; projected to reach 288 million by 2040 (Source: International AMD Epidemiology Reports)
GA Prevalence	Approx. 15-20% of AMD cases (per peer-reviewed studies)
Market Size (2023)	Estimated at $500 million (initial launch phase)
Projected CAGR (2023-2030)	25.7% (Sources: EvaluatePharma, MarketsandMarkets)

Key Driver:
The aging population and the current lack of approved treatments for GA underpin rapid market growth.

Pricing and Reimbursement Landscape

Policy Aspect	Implication
Pricing	Estimated at $5,500–$6,500 per injection (based on similar treatments like Roche's Lucentis and Bayer's Eylea)
Reimbursement	Covered under Medicare and private insurers; early coverage decisions vary by region
Cost-effectiveness	Pending pharmacoeconomic analyses; expected to influence uptake

Competitive Landscape

Competitor	Drug	Indication	Market Status	Key Differentiator
Roche/Bayer	Lucentis (ranibizumab), Eylea (aflibercept)	Wet AMD	Approved for neovascular AMD; off-label for GA	Approved for neovascular AMD, not GA
APOE-based Agents	None approved	GA	Early-stage pipeline	None currently approved for GA
Emerging	IVERIC bio's Zimura (avacincaptad pegol)	GA	Phase 3	Similar mechanism, potentially competing

Note: SYFOVRE’s primary competition during initial launch remains off-label treatments, experimental drugs, and pipeline candidates.

---

Financial Trajectory of SYFOVRE

Initial Sales Estimates (2023-2025)

Year	Estimated Revenue	Assumptions & Drivers
2023	$50–$75 million	Launch year; initial uptake in top-tier markets
2024	$150–$250 million	Growth due to expanding indications, payer adoption
2025	$350–$500 million	Increased physician familiarity, broader reimbursement

Driving Factors:

• Pricing Strategy: Premium pricing justified by lack of alternatives.
• Market Penetration: Distribution agreements and partnerships in Europe and Asia.
• Patient Access: The extent of physician adoption, patient acceptance, and affordability.

Long-Term Revenue Projections (2026-2030)

Year	Predicted Revenue	Key Assumptions
2026	$700 million	Reimbursement stabilization, healthcare policy adjustments
2027	$1.2 billion	Expanded indications, potential label expansion
2028	$1.8 billion	Entry of generics (if patent life expires), increased global access
2029	$2.4 billion	Market saturation in major regions
2030	$3 billion	Increased uptake, new combination therapies

Note: These projections incorporate potential price adjustments, government regulations, and competitive dynamics.

---

Market Challenges and Opportunities

Challenges

Challenge	Impact
Limited Long-term Data	Uncertainty over sustained efficacy and safety
Pricing & Reimbursement Hurdles	Potential delays or reductions in reimbursement coverage
Competitive Pipeline	Zimura’s phase 3 data and emerging therapies may erode market share
Manufacturing & Supply Chain	Ensuring scalability for global demand

Opportunities

Opportunity	Benefits
Expansion to Other Ophthalmic Indications	For example, ocular inflammatory diseases
Combination Therapy Development	Enhancing efficacy or reducing dosing frequency
Global Market Expansion	Especially in emerging economies with high AMD prevalence
Pricing Strategization	Tiered models, value-based pricing in different markets

---

Comparison with Market Peers

Parameter	SYFOVRE (Pegcetacoplan)	Zimura (Avacincaptad Pegol)	Lucentis/Eylea	Other Potential Entry
Mechanism	C3 complement inhibition	C5 complement inhibition	VEGF inhibition	Various mechanisms (complement, anti-VEGF)
Approval Status	Approved in 2023	Phase 3 data available	Approved	Under development
Pricing	~$6,000/injection	Similar	~$2,000/injection	TBD
Market Penetration	Early	Early	Established	Pending

Policy and Regulatory Influences

Region	Key Policies	Potential Impacts
United States	FDA approval, CMS reimbursement	Accelerates launch and access
European Union	EMA approval, national health policy	Market access; cost-effectiveness assessments
Asia-Pacific	Varying approval paths, pricing	Substantial growth potential

---

Key Factors Influencing Future Growth

Factor	Influence on Financial Trajectory
Clinical Trial Outcomes	Validates efficacy, impacts sales ramp-up
Pricing & Reimbursement Policies	Critical for adoption, especially in cost-concerned markets
Competitive Advances	New entrants or pipeline developments could dilute market share
Health Policy & Aging Demographics	Increase in eligible patients boosts sales potential
Manufacturing Capacity	Ensures supply to meet global demand

---

Conclusion

SYFOVRE’s market trajectory is promising, driven by significant unmet need, a novel mechanism of action, and favorable regulatory support. Although initial sales estimates suggest substantial revenue potential, ongoing challenges include competitive pressures, reimbursement hurdles, and safety considerations. The long-term financial outlook hinges on clinical validation, pricing strategies, and expansion into new indications and markets.

---

Key Takeaways

1. Market Potential: The global GA market is projected to reach $3 billion by 2030, with SYFOVRE capturing approximately 20–25% of the unmet need.
2. Revenue Forecast: SYFOVRE could generate over $3 billion annually by 2030 under optimal conditions of reimbursement, market access, and physician adoption.
3. Competitive Landscape: While first-in-class, SYFOVRE faces emerging pipeline candidates like Zimura; differentiation through efficacy, safety, and cost will be essential.
4. Pricing Strategy: Premium pricing justified by high unmet need; flexible models may maximize access and revenue.
5. Regulatory & Reimbursement Policies: Play a decisive role; positive policies accelerate growth, while delays could constrain sales.

---

FAQs

Q1: How does SYFOVRE compare with existing treatments for AMD?
A1: Currently, no approved treatments for GA exist; most therapies target neovascular AMD using anti-VEGF agents like Lucentis and Eylea. SYFOVRE addresses a different stage of AMD — geographic atrophy — with a novel complement inhibition approach, filling an unmet medical gap.

Q2: What factors could hinder SYFOVRE’s commercial success?
A2: Key barriers include high treatment costs, variable reimbursement policies, safety concerns over long-term use, and potential competition from pipeline therapies demonstrating superior efficacy or cost benefits.

Q3: What is the significance of approval in global markets?
A3: Approval in major regions like the EU, Japan, and China can significantly augment worldwide revenues, provided reimbursement schemes are favorable and manufacturing scales are sufficient.

Q4: Are there any safety concerns associated with pegcetacoplan?
A4: Clinical trial data demonstrate an acceptable safety profile, but long-term safety data are pending. Ongoing post-market surveillance will be critical to confirm tolerability.

Q5: How likely is market saturation by 2030?
A5: Given the increasing global prevalence of AMD and the lack of competing approved therapies for GA, SYFOVRE’s market penetration can be substantial if barriers are managed effectively. However, competition and pipeline entrants could influence saturation levels.

---

References

1. International AMD Epidemiology Reports, 2021.
2. EvaluatePharma, 2023.
3. MarketsandMarkets, 2023.
4. FDA Approval Announcement, July 2023.
5. Apellis Pharmaceuticals Investor Presentation, Q2 2023.